IDE196

Small molecule

IIDEAYA Biosciences

IDE196 is one of 50 small molecule programs targeting Uveal Melanoma. It is currently in development.

Indications

Total Trials

Active Trials

Competitors

Pipeline

Status by Indication[3][1]

Indication

Uveal MelanomaActive, not recruiting

Uveal MelanomaPhase 2/Phase 3

Active, not recruiting

Competition

Competitive Landscape

90 competitors in Uveal Melanoma

#DrugCompanyPhaseTrials

DTIC-Dome

Bayer

Phase 3

5 2

Koselugo

AstraZeneca

Phase 3

2 3

Yervoy

Bristol-Myers Squibb

Phase 2

12 4

Circadin

NNeurim Pharmaceuticals Ltd.

Phase 3

1 5

Opdivo

Bristol-Myers Squibb

Phase 2

9 6

KIMMTRAK

IImmunocore Ltd

Phase 3

5 7

Keytruda

Merck & Co.

Phase 2

6 8

Sutent

Pfizer

Phase 2

2 9

Nexavar

Bayer

Phase 2

2 10

Mekinist

Novartis

Phase 2

Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.

Timeline

Expected Milestones

Q2 2027

Phase 1/2Recruiting

Patients With Solid Tumors

NCT03947385

Q1 2028

Phase 2/3Active, not recruiting

Uveal Melanoma

NCT05987332

Clinical

Trials by Indication[1]

Patients With Solid Tumors1 trial

Study of IDE196 in Patients With Solid Tumors Harboring GNAQ/11 Mutations or PRKC Fusions

Recruiting·IIDEAYA Biosciences·Phase 1/2·NCT03947385·336 enrolled

Uveal Melanoma1 trial

IDE196 (Darovasertib) in Combination With Crizotinib as First-line Therapy in Metastatic Uveal Melanoma

Active, not recruiting·IIDEAYA Biosciences·Phase 2/3·NCT05987332·420 enrolled

Sources

References

[1]
ClinicalTrials.gov — 2 trial records for IDE196. U.S. National Library of Medicine, National Institutes of Health.
[2]
ChEMBL — IDE196 compound record. European Bioinformatics Institute (EMBL-EBI).
[3]
Open Targets Platform — Drug–disease associations for IDE196. EMBL-EBI & Wellcome Sanger Institute.
[4]
SEC EDGAR — IDEAYA Biosciences company filings. U.S. Securities and Exchange Commission.

Details

Drug Info

Quick Facts

Modality: Small molecule[2]
Company: IIDEAYA Biosciences

IDE196

Status by Indication[3][1]

Competitive Landscape

Expected Milestones

Q2 2027

Q1 2028

Trials by Indication[1]

Patients With Solid Tumors1 trial

Uveal Melanoma1 trial

References

Drug Info

Quick Facts

Related News